Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROCVIDEO: Remifentanil versus rocuronium for optimizing video laryngoscopy-assisted tracheal intubation
2025-521405-40-01Phase 4Authorised
- Sponsor
- Nordsjællands Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised trial in None comparing Remifentanil arm with Rocuronium arm (2 arms). Primary endpoints: Composite safety endpoint (early adverse events < 20 minutes), Composite safety endpoint (late adverse events < 24 hours) and 1 more. Planned start Nov 2025; status: authorised.
02
Drugs
remifentanilrocuronium
Beyond the preview
Go deeper on 2025-521405-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521405-40-01.